In the current climate of tighter budgetary controls and greater price scrutiny, a uniform pricing s...
Read moreOver the last year, the European Commission (EC) has been consulting on multiple scenarios for HTA h...
Read moreThe development of gene therapies represents a new frontier of science, with the potential to help p...
Read moreSince 2004, opportunity cost has been reflected in NICE's appraisal process through the specificatio...
Read moreThis study investigates NICE evaluations of new cancer indications and legacy CDF indications (not p...
Read morePaul Craddy is proud to be presenting at the Global Pharmaceutical Regulatory Affairs Summit in Prag...
Read moreThe Association of British Pharmaceutical Industry has been refused a legal challenge to a cap on th...
Read moreObtaining market access at the right time and at an appropriate price has become more complex for ph...
Read moreIntroduction of a new German Act - Strengthening Pharmaceutical Supply in the Statutory Health Insur...
Read moreA one stop shop for joint advice between EMA, EUnetHTA and health technology assessment bodies - the...
Read more